Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

April 4, 2019

Study Completion Date

April 4, 2019

Conditions
Chronic Liver DiseaseHepatoCellular Carcinoma
Interventions
DRUG

P03277 at 0.1 mmol/kg

P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.

DRUG

P03277 at 0.05 mmol/kg

P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.

Trial Locations (2)

49933

CHU Angers, Angers

92118

Hôpital Beaujon, Clichy

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Guerbet

INDUSTRY